MBX MBX BIOSCIENCES INC.

MBX Biosciences to Provide Topline Results from its Phase 2 Trial of Potential Once-Weekly Canvuparatide for Hypoparathyroidism (HP) on Monday, September 22

MBX Biosciences to Provide Topline Results from its Phase 2 Trial of Potential Once-Weekly Canvuparatide for Hypoparathyroidism (HP) on Monday, September 22

CARMEL, Ind., Sept. 19, 2025 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced that it will provide topline results from its Phase 2 clinical trial of potential once-weekly canvuparatide for patients with chronic hypoparathyroidism (HP) and host an investor webcast on Monday, September 22.

The Company will host a conference call and webcast at 8 am ET on Monday, September 22 to discuss the results from the Avail™ Phase 2 trial. Those who would like to participate may access the live webcast  or dial 1-877-407-0779 (US) or 1-201-389-0914 (international). The live and archived webcast of the call and slide presentation will be available in the Investors section of the Company’s website at /news-events/events.

About MBX Biosciences 

MBX Biosciences is a biopharmaceutical company focused on the discovery and development of novel precision peptide therapies based on its proprietary PEP™ platform, for the treatment of endocrine and metabolic disorders. The Company is advancing a pipeline of novel candidates for endocrine and metabolic disorders with clinically validated targets, established endpoints for regulatory approval, significant unmet medical needs and large potential market opportunities. To learn more, please visit the Company website at and follow it on .

Media Contact:

Katie Beach Oltsik

Inizio Evoke Comms



(937) 232-4889

Investor Contact:

Jim DeNike

MBX Biosciences



EN
19/09/2025

Underlying

MBXMBX BIOSCIENCES INC.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on MBX BIOSCIENCES INC.

 PRESS RELEASE
Free
MBX MBX BIOSCIENCES...

MBX Biosciences to Present at the 44th Annual J.P. Morgan Healthcare C...

MBX Biosciences to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 13 CARMEL, Ind., Dec. 15, 2025 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced that Kent Hawryluk, President and Chief Executive Officer, will present at and participate in the 44th Annual J.P. Morgan Healthcare Conference in San Francisco being held on January 12-15, 2026. 44th Annual J.P. Morgan He...

December 15, 2025 1 EN
 PRESS RELEASE
Free
MBX MBX BIOSCIENCES...

MBX Biosciences to Participate in the 37th Annual Piper Sandler Health...

MBX Biosciences to Participate in the 37th Annual Piper Sandler Healthcare Conference CARMEL, Ind., Nov. 18, 2025 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced that Kent Hawryluk, President and Chief Executive Officer, and Sam Azoulay, M.D., Chief Medical Officer, will present and participate in the 37th Annual Piper Sandler Healthcare Conference being held on December 2-4. 37th Annual P...

November 18, 2025 1 EN
 PRESS RELEASE
Free
MBX MBX BIOSCIENCES...

MBX Biosciences Reports Third Quarter 2025 Financial Results and Recen...

MBX Biosciences Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights Reported positive topline results from the Phase 2 Avail™ trial of once-weekly canvuparatide in hypoparathyroidism (HP) Completed upsized public offering, raising approximately $200 million in gross proceeds $391.7 million in cash, cash equivalents and marketable securities as of September 30, 2025; expected to support operations into 2029 Updated 2026 corporate milestones include clinical data for three Precision Endocrine Peptide™ (PEP) programs and initiation of a Phase 3 trial in HP CARMEL,...

November 6, 2025 1 EN
 PRESS RELEASE
Free
MBX MBX BIOSCIENCES...

MBX Biosciences to Participate in November Investor Conferences

MBX Biosciences to Participate in November Investor Conferences CARMEL, Ind., Oct. 20, 2025 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced that Kent Hawryluk, President and Chief Executive Officer, and Sam Azoulay, M.D., Chief Medical Officer, will present at and participate in the following upcoming investor conferences: Guggenheim 2nd Annual Healthcare Innovation Conference Date: Monda...

October 20, 2025 1 EN
 PRESS RELEASE
Free
MBX MBX BIOSCIENCES...

MBX Biosciences to Participate in the Stifel 2025 Virtual Cardiometabo...

MBX Biosciences to Participate in the Stifel 2025 Virtual Cardiometabolic Forum CARMEL, Ind., Sept. 29, 2025 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced that Kent Hawryluk, President and Chief Executive Officer, and Sam Azoulay, MD, Chief Medical Officer, will participate in a fireside chat at the Stifel 2025 Virtual Cardiometabolic Forum on September 30. Stifel 2025 Virtual Cardiometa...

September 29, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch